Clinical Trial Update: Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 open-label study of the NiV mRNA vaccine mRNA-1215 in healthy adults has completed dose escalation and reported results on safety, tolerability, and imm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nipah Virus Infection

Drugs mentioned

• mRNA-1215

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Nipah Virus Infection | Phase 1 | Status: COMPLETED | Results posted: 2025-10-23